Biomarkers
AssigneeOtago Innovation Limited
InventorsChristopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
Life of this patent
Estimating the term…
Abstract
The invention provides binding agents and assays for ghrelin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.
Claims47
A ghrelin signal peptide (GRN-SP) binding agent.
An isolated nucleic acid molecule encoding a GRN-SP fragment wherein said nucleic acid is selected from:
- (a) SEQ ID NO:18 or a variant or fragment thereof;
- (b) a sequence which has at least 70%, 75%, 80%, 85%, 90%, 95% or 99% sequence identity to SEQ ID NO:18;
- (c) a sequence of at least 10 nucleotides in length, capable of hybridising under stringent conditions to SEQ ID NO:18 or a variant or fragment thereof;
- (d) a complement of any one of (a) to (c), with the proviso that the sequence is not SEQ ID NO:16.
An assay for GRN-SP in a biological sample from a subject, the assay comprising detecting and measuring the level of GRN-SP in the sample using any known methods.
An assay for GRN-SP comprising:
- (a) binding one or more GRN-SP from a biological sample;
- and
- (b) measuring the level of bound GRN-SP.
A GRN-SP assay for use in predicting, diagnosing or monitoring a biological event or disorder in a subject.
A method for predicting, diagnosing or monitoring a biological event or disorder in a subject wherein the event or disorder correlates with the release of GRN-SP into the circulation, the method comprising:
- (a) measuring the level of GRN-SP in a biological sample from the subject;
- and
- (b) comparing the level of GRN-SP with the GRN-SP level from a control,
- wherein a deviation in the measured level from the control level is indicative of a biological event or disorder.
A method for predicting, diagnosing or monitoring diabetes, or diabetic potential in a subject, the method comprising:
- (a) measuring the level of GRN-SP in a biological sample from the subject;
- and
- (b) comparing the level of GRN-SP with the GRN-SP level from a control,
- wherein a measured level of GRN-SP lower than the control level is indicative of diabetes or a predisposition to diabetes.
A method for assessing glucose handling in a subject, the method comprising:
- (a) measuring the level of GRN-SP in a subject after administration of glucose;
- and
- (b) comparing the level of said GRN-SP with the GRN-SP from a control,
- wherein a deviation in the measured level of GRN-SP from the control level is indicative of a glucose handling disorder.
A method for predicting, diagnosing or monitoring an acute cardiac disorder (ACD) in a subject, the method comprising:
- (a) measuring the level of GRN-SP in a biological sample from the subject;
- and
- (b) comparing the level of said GRN-SP with the GRN-SP level from a control,
- wherein a measured level of GRN-SP higher than the control level is indicative of ACD.
A use of a GRN-SP binding agent for the manufacture of a GRN-SP assay for assessing a biological event or disorder in a subject.
A use of a GRN-SP binding agent in the manufacture of a prognostic, diagnostic or monitoring tool for assessing a biological event or disorder in a subject.
A kit for predicting, diagnosing or monitoring a biological event or disorder comprising a GRN-SP binding agent;
- and optionally instructions for predicting, diagnosing or monitoring a biological event or disorder in a subject from the GRN-SP level measured in a biological sample from the subject.
A kit for predicting, diagnosing or monitoring an acute cardiac disorder (ACD), comprising a GRN-SP binding agent;
- and optionally comprising instructions for predicting, diagnosing or monitoring ACD, in a subject within six or four hours of onset, or clinical presentation, from the GRN-SP level measured in the biological sample obtained within six or four hours of onset or clinical presentation with ACD.
A kit as claimed in claim 44 or claim 46 wherein the GRN-SP binding agent is a binding agent as claimed in any one of claims 1 to 6.
Dependencies are inferred from the claim text.